Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer

Journal of Cardiothoracic Surgery

Volumn 8, Issue 1, 2013, Pages

  Yan, Dong ^a   Wei, Ping ^a   An, Guangyu ^a   Chen, Wenming ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Excision repair cross complementation 1; Non small lung cancer; Number of involved lymph nodes; Prognosis; Skip metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; GEMCITABINE; PACLITAXEL; XERODERMA PIGMENTOSUM GROUP F PROTEIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CHI SQUARE DISTRIBUTION; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PNEUMONECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84878738921     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-8-149     Document Type: Article

References (28)

1. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V, Le Chevalier T. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000, 18:2981-2989.
2. Inoue M, Sawabata N, Takeda S, Ohta M, Ohno Y, Maeda H. Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe. J Thorac Cardiovasc Surg 2004, 127:1100-1106. 10.1016/j.jtcvs.2003.09.012, 15052208.
3. Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH, Eastern Cooperative Oncology Group Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg 2004, 128:130-137. 10.1016/j.jtcvs.2003.11.061, 15224032, Eastern Cooperative Oncology Group.
4. Casali C, Stefani A, Natali P, Rossi G, Morandi U. Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg 2005, 28:33-38. 10.1016/j.ejcts.2005.03.016, 15953734.
5. Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, Watanabe Y, Mitsudomi T, Yoshimura M, Japan Clinical Oncology Group Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 2001, 34:29-36. 10.1016/S0169-5002(01)00207-0, 11557110, Japan Clinical Oncology Group.
6. Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB, Li XQ. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 2010, 69:116-122. 10.1016/j.lungcan.2009.09.013, 19875192.
7. Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, Suehisa H, Kobayashi N, Aoe M, Yoshino T, Kiura K, Date H. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 2008, 59:377-384. 10.1016/j.lungcan.2007.08.025, 17905465.
8. Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep 2012, 39:6933-6942. 10.1007/s11033-012-1520-4, 22302397.
9. Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008, 60:401-407. 10.1016/j.lungcan.2007.10.014, 18036700.
10. Seyhan EC, Alti{dotless}n S, Cetinkaya E, Sökücü S, Abali H, Buyukpinarbasili N, Fener N. Prognostic significance of ERCC1 expression in resected non-small cell lung carcinoma. Ann Thorac Cardiovasc Surg 2011, 17:110-117. 10.5761/atcs.oa.09.01526, 21597406.
11. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small-cell lung cancer. Chest 2005, 127:978-983. 10.1378/chest.127.3.978, 15764785.
12. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IALT Bio Investigators DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991. 10.1056/NEJMoa060570, 16957145, IALT Bio Investigators.
13. Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, Filipits M, Brambilla E. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 2011, 78:69-78.
14. Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009, 27:5808-5815. 10.1200/JCO.2009.21.9766, 2793001, 19884554.
15. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18:317-323.
16. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2:706-714. 10.1097/JTO.0b013e31812f3c1a, 17762336, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions.
17. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological type of lung and pleural tumors. World Health Organization International Histological Classification of Tumors 1999, Berlin: Springer.
18. Goya T, Asamura H, Yoshimura H, Kato H, Shimokata K, Tsuchiya R, Sohara Y, Miya T, Miyaoka E, Japanese Joint Committee of Lung Cancer Registry Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005, 50:227-234. 10.1016/j.lungcan.2005.05.021, 16061304, Japanese Joint Committee of Lung Cancer Registry.
19. Xie L, Ugnat AM, Morriss J, Semenciw R, Mao Y. Histology-related variation in the treatment and survival of patients with lung carcinoma in Canada. Lung Cancer 2003, 42:127-139. 10.1016/S0169-5002(03)00283-6, 14568680.
20. Li J, Dai CH, Shi SB, Chen P, Yu LC, Wu JR. Prognostic factors and long term results of neoadjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients. Ann Thorac Med 2009, 4:201-207. 10.4103/1817-1737.56010, 2801045, 19881166.
21. Li J, Dai CH, Yu LC, Chen P, Li XQ, Shi SB, Wu JR. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer. Clin Lung Cancer 2009, 10:353-359. 10.3816/CLC.2009.n.048, 19808194.
22. Riquet M, Assouad J, Bagan P, Foucault C, Le Pimpec Barthes F, Dujon A, Danel C. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg 2005, 79:225-233. 10.1016/j.athoracsur.2004.06.081, 15620948.
23. Hanagiri T, Takenaka M, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, Uramoto H, Tanaka F. Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer. J Cardiothorac Surg 2011, 6:144. 10.1186/1749-8090-6-144, 3212931, 22027105.
24. Tieu BH, Sanborn RE, Thomas CR. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement. Thorac Surg Clin 2008, 18:403-415. 10.1016/j.thorsurg.2008.07.004, 19086609.
25. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360. International Adjuvant Lung Cancer Trial Collaborative Group.
26. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727. 10.1016/S1470-2045(06)70804-X, 16945766.
27. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T, LACE Collaborative Group Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559. 10.1200/JCO.2007.13.9030, 18506026, LACE Collaborative Group.
28. Leng XF, Chen MW, Xian L, Dai L, Ma GY, Li MH. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res 2012, 31:25. 10.1186/1756-9966-31-25, 3338093, 22439756.